Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Measles wipes immune memory: study reveals hidden danger

NCT ID NCT06153979

Knowledge-focused Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This completed study looked at how measles infection affects children's existing immunity and their ability to respond to vaccines. Researchers enrolled 264 children aged 1-15 in African regions, comparing those with acute measles to healthy controls. Participants received rabies vaccines at different times to measure immune response, and their antibody levels were tracked over a year.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could clarify how measles weakens the immune system, guiding better vaccination strategies and public health policies.
What could go wrong
This is an observational study, not a treatment trial. It cannot prove cause and effect, and results may not apply to all populations or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

264 people

The number who actually took part.

Started

Jan 2024

Finished

Apr 2026

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Specific study sites within each country will be in areas experiencing measles outbreaks.

Ages

1 year to 15 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 1 to 15 years. * Ability of the participant's legal or culturally acceptable representative to provide informed consent. * Ability to give assent, as appropriate. * Stated willingness of parent/guardian and participant as appropriate, to comply with all study procedures. * Willingness to receive rabies vaccine. * Meet the criteria for assignment to Group 1 or Group 2, as follows: * Group 1, cases (acute MeV infection): * Clinical signs and symptoms suggestive of acute MeV infection (Koplik spots or skin rash) AND * Laboratory confirmed measles: * Upper respiratory specimen (swab) PCR for measles positive, OR * Serum IgM for measles positive. * Group 2, controls (no acute MeV infection): * No clinical signs and symptoms suggestive of acute MeV infection (Koplik spots or skin rash) AND * Upper respiratory specimen (swab) PCR negative for MeV AND * Serum measles IgM negative AND * Serum measles IgG positive and previously vaccinated for measles (2nd dose will be offered if appropriate). If serum measles IgG is negative, participant must be willing to be vaccinated regardless of prior measles vaccine history to meet this criterion. Exclusion Criteria: * HIV infection or any other immunosuppressive condition or medications. * Pregnant or lactating. * History of prior measles or immunologic evidence of prior measles in the absence of prior measles vaccination. * Severe anemia, defined as hemoglobin less than 8 g/dL. * Any acute or chronic condition which, in the opinion of the investigator, constitutes a contraindication to participation in this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Measles infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

measles

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Measles infection

Contacts and locations

Locations

  • Partnership of Clinical Research in Guinea, Partenariat Pour La Recherche Clinique en Guinée (PREGUI)

    Conakry, Guinea

  • University Clinical Research Center (UCRC) University of Sciences, Techniques and Technologies of Bamako

    Bamako, Mali